1,2,4-Triazole derivatives, their preparation and their use for treating hypertension or respiratory tract disorders
申请人:Beecham Group p.l.c.
公开号:EP0399834A2
公开(公告)日:1990-11-28
Compounds of formula (I) and pharmaceutically acceptable salts thereof:
wherein
either one of R₁ and R₂ is hydrogen and the other is nitro, cyano, halo, CF₃ C₂F₅, formyl, aldoxime, CF₃O, NO₂-CH=CH-, NC-CH=CH-; a group RxX-wherein Rx is C₁₋₆ alkyl, aryl or heteroaryl either of which may be optionally substituted by one, two or three of C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo, CF₃ and cyano; and x is C=O, O.C=O, C=O.O, CHOH, SO, SO₂, O.SO, O.SO₂, CONH, O.CONH, C=S, O.C=S, C=S.O, CH.SH, SONH, SO₂NH, O.SONH, O.SO₂NH, CO-CH=CH, C=NHOH, C=NNH₂; or a group RyRzNZ- wherein Ry and Rz are independently hydrogen or C₁₋₆ alkyl and Z is C=O, SO or SO₂; or a group (RwO)₂P(O)W wherein Rw is hydrogen or C₁₋₆ alkyl and W is O or a bond; or
R₁ is a C₃₋₈ cycloalkyl group or a C₁₋₆ alkyl group optionally substituted by a group which is hydroxy, C₁₋₆ alkoxy, amino optionally substituted by one or two C₁₋₆ alkyl groups, C₁₋₇ alkanoylamino, C₃₋₈ cycloalkyloxy or C₃₋₈ cycloalkylamino; and R₂ is hydrogen; or
one of R₁ and R₂ is nitro, cyano or C₁₋₃ alkylcarbonyl and the other is a different group selected from nitro, cyano, halo, C₁₋₃ alkylcarbonyl, methoxy or amino optionally substituted by one or two C₁₋₆ alkyl or by C₂₋₇ alkanoyl; or
R₁ and R₂ together with the carbon atoms to which they are attached, form 2,1,3-oxadiazole;
either one of R₃ and R₄ is hydrogen or C₁₋₄ alkyl and the other is C₁₋₄ alkyl; or
R₃ and R₄ together are C₂₋₅ polymethylene;
R₅ is hydrogen, hydroxy, C₁₋₆ alkoxy or C₁₋₇ acyloxy; and
R₆ is hydrogen; or
R₅ and R₆ together form a bond;
R₇ is C₁₋₆ alkyl or phenyl C₁₋₄ alkyl optionally substituted in the phenyl ring by up to three moieties selected from C₁₋₄ alkyl, C₁₋₄ alkoxy or halo; and
R₈ is amino, hydrogen or methyl;
which are potassium channel activators, a process for their preparation and their pharmaceutical use.
式 (I) 的化合物及其药学上可接受的盐类:
其中
R₁ 和 R₂ 中的一个是氢,另一个是硝基、氰基、卤素、CF₃ C₂F₅、甲酰基、醛肟、CF₃O、NO₂-CH=CH-、NC-CH=CH-;基团 RxX,其中 Rx 是 C₁₋₆烷基、芳基或杂芳基,其中任一芳基可任选被 C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤代、CF₃ 和氰基中的一、二或三者取代;且 x 是 C=O、O.c=o、c=o.o、choh、so、so₂、o.so、o.so₂、conh、o.conh、c=s、o.c=s、c=s.o、ch.sh、sonh、so₂nh、o.sonh、o.SO₂NH、CO-CH=CH、C=NHOH、C=NNH₂;或基团 RyRzNZ-,其中 Ry 和 Rz 独立地为氢或 C₁₋₆烷基,Z 为 C=O、SO 或 SO₂;或基团 (RwO)₂P(O)W,其中 Rw 为氢或 C₁₋₆ 烷基,W 为 O 或键;或
R₁ 是 C₃₋₈ 环烷基或任选被羟基、C₁₋₆ 烷氧基取代的 C₁₋₆ 烷基、可选择被一个或两个 C₁₋₆烷基、C₁₋₇烷酰氨基、C₃₋₈ 环烷氧基或 C₃₋₈ 环烷基氨基取代的氨基;且 R₂ 为氢;或
R₁ 和 R₂ 中的一个是硝基、氰基或 C₁₋₃烷基羰基,另一个是选自硝基、氰基、卤代、C₁₋₃烷基羰基的不同基团、卤素、C₁₋₃烷基羰基、甲氧基或被一个或两个 C₁₋₆ 烷基或 C₂₋₇ 烷酰基任选取代的氨基;或
R₁ 和 R₂ 与它们所连接的碳原子一起形成 2,1,3-噁二唑;
R₃ 和 R₄ 中的一个是氢或 C₁₋₄ 烷基,另一个是 C₁₋₄ 烷基;或
R₃ 和 R₄ 合在一起是 C₂₋₅ 聚亚甲基;
R₅ 是氢、羟基、C₁₋₆ 烷氧基或 C₁₋₇酰氧基;和
R₆ 是氢;或
R₅ 和 R₆ 共同形成一个键;
R₇ 是 C₁₋₆烷基或苯基 C₁₋₄ 烷基,可选择在苯基环上被选自 C₁₋₄ 烷基、C₁₋₄ 烷氧基或卤素的最多三个分子取代;和
R₈ 是氨基、氢或甲基;
是钾通道激活剂,其制备方法和药物用途。